



2025

Taipei International Breast Cancer Symposium

台北國際乳癌研討會

Topic:

Emerging Approaches in ER+/HER2- Metastatic Breast Cancer Management

Abstract

The management of ER+/HER2- metastatic breast cancer has evolved with the use of CDK4/6 inhibitors, yet therapeutic resistance remains a key challenge, creating a critical need for effective subsequent therapies. Prof Lee will provide an overview of emerging and novel treatment strategies for patients who have progressed on ET + CDK4/6i. The importance of molecular profiling in guiding the use of treatments such as next-generation oral SERDs and PI3K/AKT inhibitors, antibody-drug conjugates (ADCs) in this patient population will be discussed.